Drug Therapy
Tolebrutinib delays onset of MS disability progression in phase 3 trial
An oral brain-penetrant therapeutic delayed the onset of confirmed disability progression compared with placebo in those with non-relapsing secondary progressive MS, according to results from a phase 3 study.
Small molecule oligomer antagonist for Alzheimer’s disease boosts brain connectivity
Results of an ongoing clinical trial showed that an oral, small molecule oligomer antagonist used to treat mild to moderate Alzheimer’s disease boosted connectivity between regions of the brain as a promising sign of cognitive improvement.
Suvorexant acutely effective in reducing Alzheimer’s-related biomarkers
PHILADELPHIA — In cognitively healthy but sleep-poor adults in midlife, treatment with 20 mg suvorexin led to acute decreases in Alzheimer’s-related biomarkers compared with 10 mg of the drug and placebo, according to a presenter.
Ajovy superior to placebo at 12 weeks for episodic migraine in young people
Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and adolescents, according to topline results from the phase 3 SPACE study.
Primary Prevention- LDL-C ≥190 mg/dL
FDA accepts supplemental new drug application of Rexulti for PTSD
The FDA has accepted a supplemental new drug application from Otsuka and Lundbeck for Rexulti in combination with sertraline to treat adults with PTSD.
Mission Therapeutics receives $5.2M to advance novel small-molecule Parkinson’s therapy
Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research and Parkinson’s UK to advance a selective, small molecule, brain penetrant USP30 inhibitor for Parkinson’s disease.
Q&A: ‘Exciting time’ for research into, development of treatments for CIDP
Although there are no current reliable tests and few treatments for chronic inflammatory demyelinating polyneuropathy, which affects about 40,000 individuals in the U.S., recent FDA approvals have made treatments a possibility.
PrimeC led to significant slowing in rate of decline in ALS at 12 months
NeuroSense Therapeutics Ltd. has reported positive results from the 12-month data analysis of a phase 2b study evaluating a novel extended-release oral formulation combination therapy in patients with amyotrophic lateral sclerosis.
VIDEO: Cenobamate effective in three administrations for focal seizures
DENVER - Cenobamate was effective in treating focal seizures administered as a whole tablet, crushed tablet or by nasogastric tube, Vijay Vashi, PhD, in this Healio video from the American Academy of Neurology annual meeting.